VPVeerle Piessens

Veerle Piessens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Veerle Piessens has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Stefan Heytens

    Department of Public Health and Primary Care, Ghent University, Ghent, Belgium

    4 shared publications
  • An De Sutter

    Affiliation Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Centre for Family Medicine, Ghent University, Ghent, Belgium

    3 shared publications
  • John Brodersen

    The Regional GP Clinic, Nykøbing Falster, Zealand University Hospital, Denmark; Department of Community Medicine, UiT – The Arctic University of Norway, Tromsø, Norway

    3 shared publications
  • Ann Van Den Bruel

    Affiliation Department of Public Health and Primary Care, Academic Centre for General Practice, KU Leuven, Leuven, Belgium

    2 shared publications
  • Ann Van Hecke

    Affiliation Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, University Centre for Nursing and Midwifery, Ghent University, Ghent, Belgium

    2 shared publications
  • Carlos Martins

    Department of Community Medicine, University of Porto Faculty of Medicine, Porto, Portugal

    2 shared publications

Latest Publications

  • Open Access

    Discrepancies in low-value practices across cardiovascular disease prevention guidelines. A narrative review

    by Carlos Brotons, Irene Moral, Tom Axelrod, John Brandt Brodersen, Carlos Martins, Serdar Öztora, Iva Petričušić, Veerle Piessens, Carlen Reyes, Laura Rodriguez-Benito, et al.

    Low-value practices are interventions that do not provide health benefits due to lack of effectiveness or associated risks that outweigh the potential benefits. The purpose of this study is to demonstrate discrepancies across various cardiovascular prevention guidelines published by numerous institutions and organisations, and establish an objective overview of the current state of the art and formulate recommendations for general practitioners. A narrative review of clinical practice guidelines for CVD prevention published in English between January 2017 and December 2025 was conducted. Searches focused on major European, British, North American, and Australian scientific societies; only guidelines containing explicit recommendations on low-value or unnecessary practices were included. We identified the scientific evidence supporting these recommendations and searched for ongoing clinical trials - specifically in cases where recommendations were based on a single randomised trial, large non-randomised studies, retrospective data, or expert opinion. Guidelines show significant discrepancies regarding recommendations for low-value practices. These primarily relate to the evaluation of the coronary artery calcium (CAC) score, determination of lipoprotein(a) (Lp(a)), screening for abdominal aortic aneurysm (AAA), and the initiation of lipid-lowering treatment in older adults. Controversy and uncertainty were most evident when recommendations were based on non-randomised clinical trials or expert opinion. While some guidelines align, others exhibit clear discrepancies, illustrating the uncertainty of the scientific evidence and differing interpretations. Until robust evidence from high-quality clinical trials becomes available, clinicians should exercise caution regarding certain screening procedures and therapeutic interventions in CVD prevention within general practice.


  • Open Access

    It depends on where you stand on screening: health professionals’ awareness, perspectives, and approaches to overdiagnosis in cancer screening - a qualitative interview study

    by Veerle Piessens, Emelien Lauwerier, John Brandt Brodersen, Melissa Ceuterick, Alexandra Brandt Ryborg Jønsson, Ann Van Den Bruel, Stefan Heytens

  • Cost-effectiveness analyses of quadrivalent influenza vaccinations in the general European population – a systematic review

    by Bram Van Sassenbroeck, Veerle Piessens, Maarten Roegies, Dominique Vandijck

    Influenza infections affect around 20% of the population annually, generally causing a mild viral syndrome, but occasionally leading to severe complications or death. Influenza vaccines, with quadrivalent influenza vaccines (QIV) as the newest generation, decrease the likelihood of infection and complications. Because both influenza infections and vaccinations impose costs on patients and on the broader society, the health gains of vaccination programs should be weighed against their financial impact. This review summarises the literature on cost-effectiveness analyses for quadrivalent influenza vaccinations compared with non-vaccination, in the general European population since 2012. We conducted a systematic review of the literature on cost-effectiveness analyses that compared quadrivalent influenza vaccination with non-vaccination. The eight included studies found that QIVs were cost-effective in 18/19 analyses at a willingness-to-pay threshold of 35 000 euro/QALY and in 15/19 analyses at 20 000 euro/QALY. Herd immunity was a major factor, as a large part of the observed cost-effectiveness gains occurred not in the targeted population for vaccination (children) but in the generations of their (grand)parents . This review suggests that vaccination programs with quadrivalent influenza programs are cost-effective compared with no influenza vaccination, regardless of the modelling assumptions. Their implementation should always be based on multiple factors, such as cost-effectiveness, the latest recommendations on optimal effectiveness for each influenza season, and ethical considerations. These results may have been influenced by the clinical and epidemiological validity of the data used by the included studies and the limited number of included analyses, most of which were industry funded.

  • Open Access

    Seven ways to optimise prevention in general practice and family medicine - a EUROPREV position paper to spark debate on prevention

    by Veerle Piessens, Laura Rodriguez Benito, Serdar Öztora, Carlos Martins, John Brandt Brodersen

    Prevention is a fundamental aspect of the work of general practitioners (GPs) and family doctors (FDs); however, its implementation poses significant challenges due to conflicting guidelines, time constraints, competing demands, and equity concerns. This position paper proposes seven guiding principles to help GPs and FDs navigate preventive care effectively. It encourages GPs/FDs to recognise the intrinsic preventive value of high-quality general practice and adopt a critical approach to the evidence underpinning preventive recommendations. Prioritising a limited number of preventive services with a strong evidence base and targeting those patients most likely to benefit will contribute to sustainable, evidence-based, and equitable patient care.


  • Open Access

    Do health professionals know about overdiagnosis in screening, and how are they dealing with it? A mixed-methods systematic scoping review

    by Veerle Piessens, Ann Van Den Bruel, An Piessens, Ann Van Hecke, John Brandt Brodersen, Emelien Lauwerier, Florian Stul, An De Sutter, Stefan Heytens

    Introduction: Medical screening is a major driver of overdiagnosis, which should be considered when making an informed screening decision. Health professionals (HPs) often initiate screening and are therefore responsible for informing eligible screening participants about the benefits and harms of screening. However, little is known about HPs’ knowledge of overdiagnosis and whether they are prepared to inform screening candidates about this risk and enable people to make an informed screening decision. Methods: This is a systematic review of studies examining HPs’ knowledge and perception of overdiagnosis, whether it affects their position on offering screening, and their willingness to inform screening candidates about overdiagnosis. We conducted systematic searches in MEDLINE, Embase, Web of Science, Scopus, CINAHL, and PsycArticles without language restrictions. Two authors analysed the qualitative and quantitative data separately. Confidence in the findings of the qualitative data was assessed using the GRADE-CERQual approach. Results: We included 23 publications after screening 9786 records. No studies directly examined HPs’ knowledge of overdiagnosis. HPs’ perceptions of overdiagnosis varied widely, from considering it a significant harm to seeing it as negligible. This seems linked to their overall beliefs about the benefits and harms of screening and to their position on offering screening, which varies from discouraging to actively promoting it. HPs also hold diverging approaches to informing screening candidates about overdiagnosis, from providing detailed explanations to limited or no information. Conclusion: There is a lack of research on HPs’ knowledge of overdiagnosis, however, HPs who do know about overdiagnosis attribute substantially different levels of harm to it. This seems intertwined with their overall beliefs about the benefits of screening, their position towards offering screening, and their willingness to inform screening candidates about overdiagnosis. This has important implications for the public’s right to evidence-based information and compromises an individual’s right to make an informed screening decision.


  • Safe Penicillin Allergy Delabeling in Primary Care: A Systematic Review and Meta-Analysis

    by Florian Stul, Stefan Heytens, Didier Gaston Ebo, Vito Sabato, Veerle Piessens


  • Open Access

    Do doctors and other healthcare professionals know overdiagnosis in screening and how are they dealing with it? A protocol for a mixed methods systematic review

    by Veerle Piessens, Stefan Heytens, Ann Van Den Bruel, Ann Van Hecke, An De Sutter

    Introduction Overdiagnosis is the diagnosis of a disease that would never have caused any symptom or problem. It is a harmful side effect of screening and may lead to unnecessary treatment, costs and emotional drawbacks. Doctors and other healthcare professionals (HCPs) have the opportunity to mitigate these consequences, not only by informing their patients or the public but also by adjusting screening methods or even by refraining from screening. However, it is unclear to what extent HCPs are fully aware of overdiagnosis and whether it affects their screening decisions. With this systematic review, we aim to synthesise all available research about what HCPs know and think about overdiagnosis, how it affects their position on screening policy and whether they think patients and the public should be informed about it. Methods and analysis We will systematically search several databases (MEDLINE, Embase, Web of Science, Scopus, CINAHL and PsycArticles) for studies that directly examine HCPs' knowledge and subjective perceptions of overdiagnosis due to health screening, both qualitatively and quantitatively. We will optimise our search by scanning reference and citation lists, contacting experts in the field and hand searching abstracts from the annual conference on 'Preventing Overdiagnosis'. After selection and quality appraisal, we will analyse qualitative and quantitative findings separately in a segregated design for mixed-method reviews. The data will be examined and presented descriptively. If the retrieved studies allow it, we will review them from a constructivist perspective through a critical interpretive synthesis. Ethics and dissemination For this type of research, no ethical approval is required. Findings from this systematic review will be published in a peer-reviewed journal and presented at the annual congress of 'Preventing Overdiagnosis'. In addition, the results will serve as guidance for further research on this topic. PROSPERO registration number CRD42021244513.


  • Open Access

    Downstream activities after laboratory testing in primary care: an exploratory outcome of the ELMO cluster randomised trial (Electronic Laboratory Medicine Ordering with evidence-based order sets in primary care)

    by Veerle Piessens, Nicolas Delvaux, Stefan Heytens, Bert Aertgeerts, An De Sutter

    Objective To estimate the rate and type of downstream activities (DAs) after laboratory testing in primary care, with a specific focus on check-up laboratory panels, and to explore the effect of a clinical decision support system (CDSS) for laboratory ordering on these DAs. Design Cluster randomised clinical trial. Setting 72 primary care practices in Belgium, with 272 general practitioners (GPs), randomly assigned to the intervention arm or the control arm. Participants The study included 10 270 lab panels from 9683 primary care patients (women 55.1%, mean age 56.5). All adult patients who consulted one of the participating GPs during the trial period and needed a laboratory exam were eligible for participation. Interventions GPs in the intervention group used a CDSS integrated into their online laboratory ordering system, while GPs in the control arm used their lab ordering system as usual. The trial duration was 6 months, with another 6 months follow-up. Main outcome measures This publication reports on the exploratory outcome of DAs after an initial laboratory exam and the effect of the CDSS on these DAs. Results 19.7% of all laboratory panels resulted in further diagnostic procedures (95% CI 18.9% to 20.5%) and 19% (95% CI 18.2% to 19.7%) in treatment changes. Check-up laboratory exams showed similar rates of DAs, with 17.5% (95% CI 13.8% to 21.2%) diagnostic DAs and 18.9% (95% CI 13.9% to 23.9%) treatment changes. Using the CDSS resulted in a significant reduction in downstream referrals (−2.4%; 95% CI −4.2% to −0.6%; p=0008), imaging and endoscopies (−0.9%; 95% CI −1.6% to −0.1%; p=0026) and treatment changes (−5.4%; 95% CI −9.5% to −1.2%; p=0.01). Conclusion This is the largest study so far to examine DAs after laboratory testing. It shows that almost one in three laboratory exams leads to further DAs, even in check-up panels. Using a CDSS for laboratory orders may reduce the rate of some DAs. Trial registration number NCT02950142.